Safeheal SAS raised €35 million (US$39.72 million) in an oversubscribed series C financing round for its temporary ...

The appointment May 6 of Vinay Prasad as the head of the U.S. FDA’s Center for Biologics Evaluation and Research (CBER) “bodes poorly” for Sarepta Therapeutics Inc.’s development-stage pipeline, said ...

Aldeyra Therapeutics Inc. is making another run at U.S. FDA clearance for reproxalap in dry eye disease (DED) after nailing ...

Actuate Therapeutics Inc. said its lead candidate, elraglusib, in pancreatic cancer demonstrated a substantial improvement in median overall survival compared to data from the same phase II study ...

Less than a week after announcing it had a new CEO, privately held Creyon Bio Inc. began a licensing and research partnership ...

Claiming that they’re suffering the consequences of a March 27 directive ordering a mass reduction in force and reorganization throughout the U.S. Department of Health and Human Services (HHS), 19 ...

Aiming to develop a systemic therapy for advanced refractory cancers, researchers have designed a novel oncolytic adenovirus that selectively targets and kills cancer cells expressing mesothelin.

Co. Ltd. showed positive results for its lead candidate, next-generation KRAS G12C inhibitor, D3S-001, also known as elisrasib, in patients with KRAS G12C mutation cancers, including patients ...

Cellecta Inc. made remote diagnostics and decentralized clinical trials significantly easier with the launch of its Drivermap Exp assay. The microsampling kit provides a “molecular snapshot” of 19,000 ...

The U.K. National Institute for Health and Care Excellence (NICE) opened a late-stage assessment for drug-eluting stents (DES) with an eye toward costs, advising clinicians that they should implant ...

PARP inhibitors have been approved for the treatment of several cancers, including ovarian, breast, pancreatic and prostate cancers with BRCA mutations or other homologous recombination repair ...

Protein phosphatase 2A (PP2A) is a key serine/threonine phosphatase that controls various signaling pathways and influences cancer development and treatment outcomes.